Print
Email
Print Edition StoriesTuesday, November 17, 2009
Life sciences software maker CambridgeSoft takes in more funds
By Mass High Tech staff
Funding drugs for rare diseases
MHT's Julie Donnelly: Life science startups finding investments
MHT's Galen Moore: Hiring trends and opportunities
CambridgeSoft Corp., a provider of life sciences software, has announced that it has closed a private equity investment from Health Evolution Partners and return backer Goldman Sachs.
The Cambridge-based firm did not disclose the amount of the recent funding, but to date, it has pulled in more than $26 million from Goldman Sachs and Edison Venture Funds.
The company develops and markets software aimed at improving productivity for the pharmaceutical, biotech, chemical and scientific research sectors. It develops its Chem & Bio Office programs in cloud computing, entreprise, workgroup and desktop versions.
In July, CambridgeSoft noted a $21 million private equity investment from Goldman Sachs & Co. in a deal that brought in Goldman Sachs vice president Raheel Zia to join CambridgeSoft’s board of directors.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
